We noticed you’re blocking ads

Thanks for visiting CRSTG | Europe Edition. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstodayeurope.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Digital Supplement | Sponsored by Elios Vision, Inc.


Earlier surgical intervention will play an increasingly important role in glaucoma management over the next several years. According to data from Market Scope, by 2027, the number of MIGS procedures is projected to double. Additionally, evidence for combined phacoemulsification and MIGS is growing.1 Technologies like ELIOS can help us to expand the treatment base of physicians who offer MIGS and take advantage of the benefits of combined procedures. Lastly, long-term outcomes are increasingly important as patients live longer with the disease.

1. Montesano G, Ometto G, Ahmed IIK, et al.Five-year visual field outcomes of the HORIZON trial. Am J Ophthalmol. 2023;251:143-155.

Keith Barton, MD, FRCP, FRCS
  • Consultant Ophthalmologist, Moorfields Eye Hospital, London
  • Professor of Ophthalmology, UCL Institute of Ophthalmology, London
  • Cofounder and Cochair of Ophthalmology Futures Forum and the International Glaucoma Surgery Registry
  • Financial disclosure: Consultant (Elios Vision)